Navigation Links
my1HIE(sm) Implements WellCentive Registry
Date:1/26/2009

ATLANTA and BINGHAM FARMS, Mich., Jan. 26 /PRNewswire/ -- WellCentive, LLC today announced that WellCentive Registry has been selected by my1HIE(sm) (My One Health Information Exchange) as its patient registry and disease management system.

Through the use of WellCentive Registry, more than 1,000 my1HIE physicians and other health care providers in Southeast Michigan will be better able to provide preventive care services and track and manage patients with chronic health conditions, such as diabetes, asthma or heart disease. WellCentive Registry combines the capabilities of a Web-based, community-wide, point-of-care all-patient registry system with custom interfacing, customizable alerts, targeted patient outreach, comprehensive reporting tools, secure messaging features and direct reporting of outcomes to a variety of payors. WellCentive Registry includes highly effective patient outreach tools, including an integrated automated telephone appointment and care reminder system called WellCentive Outreach.

"Michigan led the industrial age with manufacturing, and we are now a driving force in the health care industry's adoption of new technologies by means of connecting physicians, labs, health plans, hospitals, electronic prescribing and other clinical applications -- with physicians leading the way," said Steven D. Grant, MD President and CEO of United Physicians, PC. "This new partnership with WellCentive gives us an opportunity to expand the platform we initially created with my1HIE and continue to advance the physician adoption of innovative technology."

my1HIE is a unique, physician-driven health information exchange launched in November 2008. With the physician and their respective physician organization at the forefront of the complete health information exchange, four physician organizations representing more than 3,000 physicians are already committed to my1HIE, and there are discu
'/>"/>

SOURCE WellCentive
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. XTL Biopharmaceuticals Implements Restructuring Plan
2. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
3. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
4. New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration
5. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
6. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
7. WellCentive Launches New Health Information Exchange Platforms
8. WellCentive Launches New Secure Messaging Platform for Its Patient Registry System
9. CAS Registers 40 Millionth Substance in CAS REGISTRY(SM)
10. EMD Serono Launches Landmark Patient Registry for Egg Freezing
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 2Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 4Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 5Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 6Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 7Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 8Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 9Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 10Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 11Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 12Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 13Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 14Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 15Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 16Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 17